(CRDL) Update: Coming Out Strong Behind Bullish Technicals, A New 52-Week High Was Just Reached

Nasdaq breakout idea (CRDL) is hot to trot this morning. (CRDL) Update: Coming Out Strong Behind Bullish Technicals, A New 52-Week High Was Just Reached June 12th Dear Reader, Nasdaq breakout idea (CRDL) is hot to trot this morning. Making moves ahead of the opening bell, this must-know profile could start attracting a ton of buzz. Surging green early, CRDL has several triggered technical indicators across the short, medium, and long term over at [Barchart](. The website's important "Trend Seeker" composite indicator is also triggered at the moment. Additionally, by breaking the $3.00 barrier, CRDL has now posted a new 52-week high. Could more be on the way? Take a look at CRDL's [chart](. Right now, CRDL is trading above 3 very important technical lines in its 50-Day Simple Moving Average (SMA), its 200-Day SMA, and its 13-Day Exponential Moving Average (EMA). If potential support strengthens at those levels, it could allow for CRDL to continue its vertical trend we've witnessed over the past several months. Take a moment now to review my initial (Nasdaq: CRDL) report below, but don't take too long to get this breakout idea on your screens this morning! ----- Over the past few days, I've spent time following up on an alert I signaled a while back. Alerted after closing on September 20th, 2023, at $.99, this Nasdaq past champ has been on an absolute heater. From that close to Tuesday's high of $2.98 (also a 52-week high), this mover and shaker has run approximately 202%! With [analyst targets]( of $8.00 and $9.00 making the rounds and suggesting over 100% potential upside each, this under-the-radar idea could start attracting Wall Street's attention in a big way. Why? For multiple reasons. Here's a quick two to sink your teeth into right now: #1. The company has been hinting at important news to drop in Q2 that, if positive, could generate some serious breakout buzz. #2. Bullish technical indicators. [Barchart]( is reporting a multitude of triggered technicals across the short, medium, and long term. On top of that, the website's "Trend Seeker" composite indicator is also triggered at the moment. With several other 2024 press releases pointing to a company moving towards disruption of a critical multi-Bn dollar market, now might be the best time to get this Nasdaq profile on your radar before others beat you to it. Drop everything right now and pull up: *Cardiol Therapeutics Inc. (CRDL)* Cardiol Therapeutics Inc. is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company’s lead small molecule drug candidate, CardiolRx™ (cann-a-bidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. And right now CRDL has several must-know potential catalysts that could provide it with a near term breakout spark. Check them out: No. 1 - Multiple Technical Indicators Triggered Bullish (10+ In All!) No. 2 - Analysts Are Buzzing With Significant Price Targets. No. 3 - Topline Results For MAvERIC-Pilot Phase II Study To Drop This Month! No. 4 - The US FDA Grants Orphan Drug Designation For CRDL's Lead Drug Candidate, CardiolRx™. But more on those in a second... Cardiol's Immediate Focus The company is focused on understanding how inflammation and fibrosis contribute to diseases of the heart and to develop therapies, now in clinical trials for rare cardiac conditions, to target these mechanisms and promote healing. Pericarditis Pericarditis is the most common form of pericardial disease with a prevalence of 160,000 in the United States; following an initial episode, 15 – 30% of patients experience a recurrence. Pericarditis refers to inflammation of the membrane or sac that surrounds the heart (the pericardium) that is most frequently triggered from a viral infection. Recurrent pericarditis is the most common complication following an initial acute episode of pericarditis, and patients may have multiple recurrences. Symptoms include debilitating chest pain, shortness of breath, and fatigue, resulting in physical limitations, reduced quality of life, emergency department visits, and hospitalizations. Infrequent but life-threatening complications associated with pericarditis include a large accumulation of pericardial fluid, scarring, and constriction of the heart which may limit heart function. The disease is diagnosed in 0.2% of all cardiovascular in-hospital admissions and is responsible for 5% of emergency room admissions for chest pain in North America and Western Europe. Cardiol is conducting a Phase II open-label pilot study (MAvERIC-Pilot) designed to evaluate the tolerability, safety, and efficacy of their lead investigational drug, CardiolRx™, in patients with recurrent pericarditis. The study will also assess the improvement in objective measures of disease, and during an extension period, assess the feasibility of weaning concomitant background therapy including corticosteroids, while taking CardiolRx™. ----- Myocarditis Acute myocarditis is a leading cause of sudden cardiac death in people under 35 years of age. Myocarditis is an acute inflammatory condition of the heart muscle (myocardium) characterized by chest pain, impaired cardiac function, atrial and ventricular arrhythmias, and conduction disturbances. Although the symptoms are often mild, myocarditis remains an important cause of acute and fulminant heart failure and is a leading cause of sudden cardiac death in people under 35 years of age. Although viral infection is the most common cause of myocarditis, the condition can also result from bacterial infection, commonly used drugs and mRNA vaccines, as well as therapies used to treat several common cancers, including chemo-therapeutic agents and immune checkpoint inhibitors. CardiolRx™ is currently being evaluated in a Phase II multi-national study (ARCHER) to evaluate its safety and tolerability as well as its impact on myocardial recovery, in patients presenting with acute myocarditis. ARCHER is expected to enroll 100 patients at major cardiac centers in North America, Europe, Latin America, and Israel. ----- Heart Failure Heart failure affects more than 64 million people globally and associated healthcare costs exceed $30Bn annually in the U.S. alone. Heart failure is a chronic, progressive syndrome in which the heart muscle is unable to pump enough blood to meet the body’s needs for blood and oxygen. People with heart failure suffer from shortness of breath, rapid heart rate, edema, reduced exercise capacity, often struggle with simple daily activities, and are frequently hospitalized. For many, these symptoms significantly reduce their quality of life. Known causes of heart failure include ischemic heart disease and myocardial infarction (heart attack), hypertension, valvular heart disease, inflammatory diseases of the heart such as myocarditis and cardiomyopathies, anti-cancer therapies, and inherited metabolic diseases. CRD-38 is their novel proprietary drug formulation designed to deliver cann-a-bidiol by subcutaneous administration. They are undertaking IND-enabling activities to support clinical evaluation of CRD-38 as a therapeutic strategy in heart failure care. ----- The Inflammasome Inflammasomes are large, intracellular, multiprotein, sensor complexes which under normal conditions are essential to innate immunity and maintaining homeostasis. The NLRP3 (NACHT, leucine-rich repeat, and pyrin domain-containing protein 3) inflammasome is the most extensively studied. Aberrant activation of inflammatory pathways, including the NLRP3 inflammasome, occurs under various conditions such as obesity, hypertension, diabetes, and autoimmunity, or in response to a trigger (e.g., viral infection). This activation contributes to the release of cytokines (IL-1β; IL-6; IL-18) and mechanisms (pyroptosis; endothelial dysfunction) which lead to a cycle of inflammation and fibrotic responses. These responses are associated with contributing to the pathogenesis and progression of heart diseases including pericarditis, myocarditis, and heart failure. The exact mechanism by which their investigational drugs inhibit inflammation and fibrosis is not fully elucidated; however, their research and that of others suggests that the active pharmaceutical ingredient in CardiolRx™ and CRD-38 attenuates multiple inflammatory signaling pathways, including inhibiting activation of the NLRP3 inflammasome. By targeting inflammatory signaling pathways, their approach has therapeutic potential to heal the heart. ----- Product Pipeline Therapeutic Development - CardiolRx™ CardiolRx™ oral solution is in clinical development for use in the treatment of heart disease. CardiolRx™ attenuates multiple inflammatory signaling pathways, including inhibiting activation of the NLRP3 inflammasome, which is known to play an important role in the inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure. CardiolRx™ is pharmaceutically manufactured under cGMP to meet the highest standards for product purity, consistency, and stability. A Phase I safety and pharmacokinetic study of single and multiple ascending doses of CardiolRx™ was completed and demonstrated that CardiolRx™ was safe and generally well tolerated at all dose levels, with no serious adverse events reported. The results supported the Company’s two Investigational New Drug Application authorizations from the United States Food and Drug Administration to conduct two Phase II studies in rare heart diseases: recurrent pericarditis and acute myocarditis. The Company plans to pursue the development of CardiolRx™ as an orphan drug for the treatment of these heart conditions under the U.S. Orphan Drug Designation program and the European Medicine Agency’s orphan medicine product program. Sources: [Company Website.]( [Company Presentation.]( ----- As mentioned above, CRDL has multiple potential breakout catalysts to start focusing on right now. Take a look: No. 1 CRDL Potential Catalyst - Multiple Technical Indicators Triggered Bullish (10+ In All!). I'm telling you right now... Don't discount CRDL's bullish technical indicators. At close 1:00PM EST Tuesday, CRDL was displaying several triggered technical indicators across the short, medium term, and long term. [Barchart]( was reporting these as triggered: Short Term Indicators - 20 Day Moving Average - 20 - 50 Day MACD Oscillator - 20 - 100 Day MACD Oscillator - 20 - 200 Day MACD Oscillator Medium Term Indicators - 50 Day Moving Average - 50 - 100 Day MACD Oscillator - 50 - 150 Day MACD Oscillator - 50-200 Day MACD Oscillator Long Term Indicators - 100 Day Moving Average - 150 Day Moving Average - 200 Day Moving Average - 100 - 200 Day MACD Oscillator The website also shares its all-important "Trend Seeker" composite indicator is triggered. Watch these technicals closely this week. ----- No. 2 CRDL Potential Catalyst - Analysts Are Buzzing With Significant Price Targets. Take a look at what [TipRanks]( is reporting: Right now there are at least 2 analysts pointing towards CRDL being undervalued at current levels. With an average target of $8.50, that suggests a potential upside of over 100% from CRDL's 1:00PM EST valuation on Tuesday afternoon. And as we've seen over the past 6 months, [CRDL has been heating up](... Could these targets be reachable before the end of 2024? ----- No. 3 CRDL Potential Catalyst - Topline Results For MAvERIC-Pilot Phase II Study To Drop This Month! Cardiol Therapeutics Announces Phase II ARCHER Trial Presented at the World Congress on Acute Heart Failure 2024 Scope of presentation included trial design, rationale, and blinded baseline data on first 50 patients randomized into the Phase II study evaluating CardiolRx™ in patients with acute myocarditis ARCHER trial rationale and design also accepted for publication in the journal ESC Heart Failure ARCHER trial has now exceeded 85% of target patient enrollment MAvERIC-Pilot Phase II study investigating CardiolRx™ for recurrent pericarditis expected to report topline results in early June 2024 Toronto, Ontario--(Newsfile Corp. - May 14, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"),..., today announced its Phase II randomized, double-blind, placebo-controlled trial evaluating the impact of CardiolRx™ on myocardial recovery in patients with acute myocarditis ("ARCHER") was the subject of an oral presentation at the World Congress on Acute Heart Failure 2024, May 11 - 14 in Lisbon, Portugal - the annual congress of the Heart Failure Association of the European Society of Cardiology ("ESC"). The trial design, rationale, and blinded baseline data on the first 50 patients randomized into ARCHER was presented by Univ.-Prof. Dr. med. Carsten Tschöpe from the Berlin Institute of Health - Charité, on behalf of the ARCHER steering committee comprising distinguished thought leaders in heart failure and myocarditis from international centers of excellence who contributed to the design and execution of ARCHER. Concurrent with the presentation, the journal ESC Heart Failure, which is dedicated to advancing knowledge about heart failure worldwide, has accepted the manuscript describing the rationale and design of the ARCHER trial for publication. "Acceptance to present the ARCHER trial design at such a prestigious scientific meeting and pending publication of the manuscript is testament to the high level of interest from the cardiology community in novel approaches to treat acute myocarditis for which there are currently no therapies approved by European and United States regulatory authorities. The baseline data from the first 50 ARCHER patients reveal demographics expected in acute myocarditis. Importantly, the initial baseline values of the primary and secondary outcome measures assessing myocardial function reveal low variability and reflect patients with acute myocarditis which is consistent with the patient segment expected to benefit from CardiolRx™ therapy," commented David Elsley, President and Chief Executive Officer of Cardiol Therapeutics. "Patient recruitment has been accelerating due in large part to the growing global awareness of myocarditis and the interest and commitment demonstrated by our clinical collaborators and participating patients. We are pleased to report ARCHER has now exceeded 85% of target enrollment. We anticipate that results from the ARCHER trial will assist in furthering our understanding of the therapeutic potential of CardiolRx™ and will complement our more advanced MAvERIC-Pilot Phase II study in patients presenting with recurrent pericarditis, expected to report topline results in early June 2024." ... [Read the full article here.]( ----- No. 4 CRDL Potential Catalyst - The US FDA Grants Orphan Drug Designation For CRDL's Lead Drug Candidate, CardiolRx™. Cardiol Therapeutics Granted Orphan Drug Designation for its Lead Drug Candidate for the Treatment of Pericarditis Designation Based on Pre-Clinical Data and Initial Clinical Data from the Company's MAvERIC-Pilot Phase II Study Toronto, Ontario--(Newsfile Corp. - February 15, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), ..., announces that the United States Food and Drug Administration ("FDA") has granted Orphan Drug Designation ("ODD") for the Company's lead small molecule drug candidate for the treatment of pericarditis, which includes recurrent pericarditis. CardiolRx™ is currently in Phase II clinical trials for recurrent pericarditis and acute myocarditis. "The FDA's decision was based on pre-clinical data combined with initial clinical data from the Company's MAvERIC-Pilot Phase II study," commented Dr. Andrew Hamer, Cardiol Therapeutics' Chief Medical Officer and Head of Research & Development. "This designation reinforces the potential of CardiolRx™ to improve the lives of patients suffering with recurrent pericarditis, a debilitating heart disease associated with symptoms that adversely affect quality of life and physical activity." The FDA grants ODD to a drug or biological product to prevent, diagnose, or treat a rare disease or conditions that affect fewer than 200,000 people in the United States. ODD provides benefits to sponsors including potential seven-year marketing exclusivity, exemptions from certain FDA fees, and tax credits for qualified clinical trials. Products with ODD may also qualify for accelerated regulatory review via Fast Track, Breakthrough Therapy, or Priority Review designations. ... [Read the full article here.]( ----- (Nasdaq: CRDL) Recap - These Potential Catalysts Could Fuel A Breakout Spark No. 1 - Multiple Technical Indicators Triggered Bullish (10+ In All!) No. 2 - Analysts Are Buzzing With Significant Price Targets. No. 3 - Topline Results For MAvERIC-Pilot Phase II Study To Drop This Month! No. 4 - The US FDA Grants Orphan Drug Designation For CRDL's Lead Drug Candidate, CardiolRx™. ----- Coverage is officially reinitiated on (Nasdaq: CRDL). I'll be in touch with updates as we move forward. Get this breakout idea pulled up now. Sincerely, FierceAnalyst | Jaks Swift Editorial Writer (Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.) Fierce | 4834 NW 2nd Ave Unit #388 | Boca Raton, FL 33431 US [Unsubscribe]( | [Update Profile]( | [Constant Contact Data Notice](